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We investigated the eﬀect of food on the steady-state pharmacokinetics of a proprietary ﬁxed-dose combination (FDC) tablet
containing tenofovir disoproxil fumarate (TDF)/emtricitabine/efavirenz. Fifteen Ugandan HIV-1 patients at steady-state dosing
with TDF/emtricitabine/efavirenz were admitted for 24-hour intensive pharmacokinetic sampling after dosing in the fasting
state. Blood sampling was repeated seven days later with TDF/emtricitabine/efavirenz administered with food (19g fat). Drug
concentrations in plasma were determined by liquid chromatography and tandem mass spectrometry. Geometric mean ratios
(GMRs) and conﬁdence intervals (CIs) of parameters were calculated (reference, fasting). For efavirenz, GMRs (90% CIs) for
Cmax,A U C 0−24,a n dC24 were 1.47 (1.24–1.75), 1.13 (1.03–1.23), and 1.01 (0.91–1.11), respectively. Corresponding GMRs were
1.04 (0.84–1.27), 1.19 (1.10–1.29), and 0.99 (0.82–1.19) for tenofovir, 0.83 (0.76–0.92), 0.87 (0.78–0.97), and 0.91 (0.73–1.14) for
emtricitabine. Stable patients may take the FDC without meal restrictions. The FDC should be taken without food by patients
experiencing central nervous system toxicities.
1.Introduction
Food intake around the time of drug dosing may alter the
bioavailability of orally administered drugs, and food eﬀects
c a nv a ryf r o md r u gt od r u g[ 1]. For ﬁxed-dose combinations
(FDCs), food intake may have an unbalanced impact on the
component drugs and consensus must be achieved on the
meal condition which results in optimal drug exposure for
the overall regimen. Tenofovir disoproxil fumarate (TDF)
and emtricitabine plus efavirenz is recommended for ﬁrst-
line treatment of HIV-1-infected adults [2–4]. These drugs
were released as a single FDC tablet in 2006 following
demonstration of bioequivalence between the FDC and the
individual dosage forms [5].
Prior to the release of the FDC formulation, manufac-
turers of individual formulations had issued divergent guid-
ance on food intake during drug dosing. In a single-dose
study, a high-fat meal increased exposure (area under the
curve, AUC) of TDF by 40% leading to a recommendation
to dose TDF along with a meal [6]. Similarly, a high-fat meal
increased AUC and maximal concentrations (Cmax)o fe f a -
virenz by 28% and 79%, respectively. In this instance, the
manufacturer recommended that efavirenz be administered
without food because elevated efavirenz concentrations2 AIDS Research and Treatment
may lead to an increased frequency of adverse events [7].
Emtricitabine exposures were unaﬀected by food intake;
therefore, the manufacturer recommended that it could be
taken without regard to food [8].
Currently, the manufacturers of the FDC recommend
that the tablet be administered without food. However, the
new tablet formulation has not been formally evaluated in
the presence of food [9]. Ugandan antiretroviral guidelines
prefer drugs that are administered without food restrictions
[4]. In Uganda, certain patients may prefer to dose their
drugs with food because they believe that all antiretroviral
drugs must be taken with food to prevent side eﬀects [10].
Although this belief is unfounded, regimens which must be
administered without food may be less acceptable to this
group of patients.
In order to determine if the FDC can be administered
with food, the current study compared the steady-state phar-
macokinetics of tenofovir, emtricitabine, and efavirenz dur-
ingadministrationofaproprietaryFDCcontainingTDFand
emtricitabine plus efavirenz in the fasting state or with a
moderate-fat meal in HIV-1-infected Ugandan adults.
Western meals used in food eﬀect studies can greatly dif-
fer from meals consumed in African settings, and pharma-
cokinetic data are scarce in African patients receiving local
meals. Therefore, the present study was conducted using a
local Ugandan meal.
2. Methods
2.1. Ethics and Regulatory Approval. Ethics committee ap-
proval was granted by the Joint Clinical Research Centre
(JCRC) Institutional Review Board (Study code: JAFS). The
trial was registered with the UNCST (HS553) and on http://
www.pactr.org/ (PACTR2009120001702102).
2.2. Study Design. HIV-1-infected patients receiving TDF
and emtricitabine plus efavirenz (Atripla, Bristol Myers
Squibb & Gilead Sciences LLC) one tablet daily for greater
than one month were recruited into this open-label, two-
phase, single-sequence, cross-over pharmacokinetic study.
2.3. Patients. T h es t u d yw a sc o n d u c t e da tJ C R CM e n g o ,
Kampala. Patients were enrolled if they provided written in-
formed consent, were between 18 and 65 years of age, and
hadnorecentuseofmedications(includingtraditionalmed-
icines) known to interfere with cytochrome P450 (CYP) me-
tabolism.Patientswereexcludediftheywereanaemic(serum
haemoglobin <10g/dL), had signiﬁcant derangement in re-
nal function (serum creatinine >3.4mg/dL) or hepatic func-
tion (serum alanine transaminase >5 times the upper limit
of normal), or if they had severe intercurrent illnesses, vom-
iting, or diarrhoea or were unable to adhere to the prescribed
meal sequence of the study. Women were excluded if they
were pregnant.
2.4. Pharmacokinetic Sampling. Enrolled patients attended
two 24-hour intensive pharmacokinetic sampling visits
scheduled one week apart (day 1 and day 8). Patients taking
their antiretroviral drugs at night were switched to morning
dosingofaminimumof3daysbeforetheﬁrstsamplingvisit.
On the morning of Day 1 (fasting), one FDC tablet of TDF
and emtricitabine plus efavirenz (300mg/200mg/600mg,
resp.) was administered to patients after an overnight fast.
Blood samples were collected before dosing and at 0.5,
1, 2, 3, 4, 6, 8, 12, and 24 hours after dosing. Breakfast
was provided 3-4 hours post-dosing (see below for details).
At each time point, 4mL of venous blood was collected
into ethylenediaminetetraacetic-acid-containing tubes, and
samples were transferred to the JCRC laboratory within 1
hour of collection. Blood samples were centrifuged at 1500g
for 10 minutes to obtain plasma. Plasma obtained during
centrifugationwastransferredinto2mLcryovialsandstored
at −70◦C pending sample shipment. After collection of
the blood sample at the 24-hour time-point, patients were
allowed home and scheduled for a repeat pharmacokinetic
evaluation one week later.
On Day 8 patients were readmitted after an overnight
fast and given a standardized moderate fat Ugandan meal.
The meal contained 650 Kcal and was composed of approxi-
mately19goffat.Themealcontentsincludedmatooke(local
bananas,cooked vegetables,oilandmeat,andteawithmilk).
Meals were started and completed within the 30 minutes
prior to the scheduled time of TDF and emtricitabine plus
efavirenz dosing. Blood sampling and plasma processing
were conducted as in Day 1.
2.5. Determination of Tenofovir, Emtricitabine, and Efavirenz.
The laboratory phase was conducted at the Department of
Molecular and Clinical Pharmacology, University of Liver-
pool. Plasma samples were pretreated at 58◦Cf o r4 0m i n u t e s
to inactivate HIV-1 and other pathogens. Tenofovir and
emtricitabine were isolated from plasma by protein precip-
itation and solid-phase extraction, and concentrations were
determinedusingatriplequadrupoleliquidchromatography
withtandemmassspectrometry(LC-MS/MS).Analyteswere
resolved on a phenomenex Synergi Polar C18 reverse phase
4µ (150 × 2mm) column. The lower limit of quantiﬁcation
(LLOQ) for tenofovir was 5.4ng/mL, accuracy ranged from
86.0 to 95.1%, and imprecision was below 16.5%. The LLOQ
for emtricitabine was 6.8ng/mL, accuracy ranged from 95.5
to 101.0%, and imprecision was below 11.3%.
Efavirenz was isolated from plasma by protein precip-
itation, and the concentration was determined using LC-
MS/MS. Hexobarbital was used as the internal standard.
The analytic column was an Atlantis C18 reverse phase 3µ
(50 × 2.1mm) LC column. The LLOQ for efavirenz was
8.5ng/mL. Assay accuracy ranged from 93.2 to 101.8%, and
imprecision was below 7.5%.
The laboratory participates in an external quality control
program for antiretroviral drugs/(http://www.kkgt.nl/)
2.6. Safety Assessments. Reported adverse events were re-
corded at pharmacokinetic sampling visits.
2.7. Data Analysis. Patient demographic parameters are pre-
sented as summary statistics (medians, interquartile ranges).AIDS Research and Treatment 3
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Figure 1: 24-hour plasma-concentration-time proﬁles of (a) tenofovir, (b) emtricitabine, and (c) efavirenz when administered in the fed
and fasting states. Error bars, standard error.
Pharmacokinetic parameters including maximal concentra-
tions (Cmax), time to Cmax (Tmax), and concentrations 24
hours after dosing (C24) were obtained from the data. The
AUC over 24 hours (AUC0−24) and half-life (t1/2)w e r e
calculated by noncompartmental methods (WinNonlin Ver-
sion5.2, Pharsight, MountainView, CA, USA). Values for
Tmax are presented as medians and interquartile ranges.
Geometric means (GMs) and ratios (GMRs) were calcu-
lated for AUC0−24, Cmax,a n dC24. The fasting state (Day 1)
was used as the reference based on the manufacturer’s rec-
ommendation to dose the FDC without food. Absence of a
food eﬀect was assumed if the 90% CI for GMR between fed
and fasting treatments was not contained in the equivalence
limits of 80–125% for either AUC0−24 or Cmax.T e n o f o vi ra n d
emtricitabinet1/2 waspresentedasharmonicmeansand90%
CI. The 24-hour dosing interval is inadequate to characterise
efavirenz t1/2, and these results are not presented. Efavirenz
plasma concentrations 12 hours after dosing (C12)w e r e
evaluated using the suggested therapeutic range of 1,000–
4,000ng/mL based on a study in which efavirenz samples
were collected between 8 and 20 hours after dosing [11].
3. Results
3.1. Patients. Demographic characteristics of patients at
screening are shown in Table 1. Of the 15 patients enrolled,
11 were male. At enrolment, patients were on treatment with
the TDF and emtricitabine plus efavirenz FDC for a median
(interquartile range) of 413 (210–600) days. Fourteen pa-
tients were receiving cotrimoxazole prophylaxis while one
patient was on dapsone. All 15 patients completed the study.
3.2. Pharmacokinetics. Figure 1 shows 24-hour plasma-con-
centration-time proﬁles for tenofovir, emtricitabine, and
Table 1: Patient characteristics at screening.
Parameter Median (interquartile range)
Age (years) 43 (40–50)
Weight (kg) 74 (69–80)
Height (m) 1.70 (1.68–1.75)
CD4 (cells/µL) 355 (312–419)
Hb (g/dL) 14.9 (13.1–15.3)
Alanine transaminase (IU/L) 25 (17–32)
Aspartate transaminase (IU/L) 23 (20–27)
Blood urea nitrogen (mg/dL) 10 (8–13)
Creatinine (mg/dL) 0.87 (0.78–0.94)
efavirenz under fed and fasting dosing conditions. Plasma
pharmacokinetic parameters and comparisons for these
three drugs are presented in Table 2. Figure 2 displays in-
dividual AUC0−24, Cmax,a n dC24 of the study drugs when
administered under fasting and fed conditions.
Median(interquartilerange)tenofovirTmax was2.0(1.5–
3.0) hours in the fasting state and 3.0 (2.0-3.0) hours with
food. Tenofovir AUC0−24 was signiﬁcantly increased by 19%
in the presence of food while other parameters were not
signiﬁcantly altered by food intake. In the fasting and fed
states, CVs for AUC0−24 was 48% and 43%; Cmax was 65%
and 74%; C24 was 57% and 41%, respectively. Other param-
eters were not signiﬁcantly altered by the presence of food.
On Day 1 and Day 8, t1/2 was 10.3 (9.8–12.1) and 8.9 (8.4–
10.4) hours, respectively.
For emtricitabine, Tmax was 1.0 (1.0-2.0) hours in the
fastingstateand3.0(2.0–3.5)hourswithfood.Emtricitabine
Cmax and AUC0−24 were signiﬁcantly lower with food (17%
and 13%, resp.) while C24 was unchanged. In the fasting and4 AIDS Research and Treatment
Table 2:Pharmacokinetic parameters andcomparisonsduringtenofovir andemtricitabine plus efavirenz administrationin thefasting(Day
1) and fed (Day 8) states.
Parameter GM (95% CI) GMR (90% CI)
Fasting∗ Fed Fed/Fasting
Cmax (ng/mL) 169 (137–255) 175 (136–275) 1.04 (0.84–1.27)
Tenofovir AUC0−24 (ng·h/mL) 1316 (1117–1748) 1568 (1369–2032) 1.19 (1.10–1.29)
C24 (ng/mL) 27 (23–39) 27 (23–34) 0.99 (0.82–1.19)
CL/F(0−24) (L/h) 186 (168–231) 156 (139–198) 0.84 (0.78–0.91)
Cmax (ng/mL) 1043 (935–1233) 870 (789–1016) 0.83 (0.76–0.92)
Emtricitabine AUC0−24 (ng·h/mL) 7029 (6300–8313) 6115 (5642–6846) 0.87 (0.78–0.97)
C24 (ng/mL) 67 (57–92) 61 (53–81) 0.91 (0.73–1.14)
CL/F(0−24) (L/h) 28 (26–33) 33 (30–37) 0.89 (0.80–0.99)
Cmax (ng/mL) 3128 (2678–4203) 4611 (3961–6037) 1.47 (1.24–1.75)
Efavirenz AUC0−24 (ng·h/mL) 46299 (37411–69475) 52194 (41827–76643) 1.13 (1.03–1.23)
C24 (ng/mL) 1395 (1082–2335) 1408 (1073–2448) 1.01 (0.91–1.11)
CL/F(0−24) (L/h) 13 (11.6–17.3) 12 (10.5–14.4) 0.89 (0.81–0.97)
GM: geometric means; GMR: geometric mean ratio; CI: conﬁdence intervals, Cmax: maximum concentration; C24: concentration 24 hours after dosing;
AUC0−24: area under the concentration-time curve; CL/F: clearance.
∗reference.
fed states, CVs for AUC0−24 were 48% and 43%; Cmax was
65% and 74%; C24 was 57% and 41%, respectively. On Day
1 and Day 8, t1/2 was 6.1 (5.8–6.8) and 4.8 (4.5–5.7) hours,
respectively.
For efavirenz, Tmax was 3.0 (2.0–4.0) hours in the fasting
state and 3.0 (3.0–6.0) hours with food. Efavirenz AUC0−24
and Cmax were signiﬁcantly increased in the fed state by
13% and 47%, respectively, while efavirenz C24 was identical
under both meal conditions. High inter-individual variabil-
ity was observed for C24 (80% and 85%) in the fasting and
fed states, respectively. For these two meal conditions, CV
for AUC0−24 was 66% and 64% and Cmax was 48% and 45%,
respectively. Two individual patients (number 05 and num-
ber 10) had unusually high efavirenz concentrations. For
these two patients, efavirenz AUC0−24 ranged from 119,178
to155,895ng·h/mL on both sampling visits (Figure 2(c)).
These patients were the only two patients with C12 values
above 4000ng/mL. Their respective C12 were 4,968ng/mL
and 6067ng/mL without food and 6,300 and 5936ng/mL
with food. The C24 measured below 1,000ng/mL in ﬁve
patients in the fasting state and four patients in the fed state.
3.3. Safety. No study-related adverse events were reported.
4. Discussion
Efavirenz trough concentrations were similar under both
meal conditions; however, peak concentrations were in-
creased by 47% during administration with a moderate-
fat Ugandan meal. However, food did not alter the pro-
portion of patients with efavirenz concentrations above the
threshold of 4,000ng/mL 12 hours after dosing. In 2001,
Marzolini et al. reported an approximately 2.5-fold increase
in the frequency of sustained central nervous system (CNS)
toxicity among patients with efavirenz concentrations above
4,000ng/mL versus patients with concentrations between
1,000 and 4,000ng/mL [11]. However, this threshold was
not conﬁrmed in a larger analysis which found a correlation
between symptoms and plasma levels only in the ﬁrst week
of treatment [12], instead single-nucleotide polymorphisms
of drug-metabolizing enzymes were shown to be more pre-
dictive of efavirenz pharmacokinetics and clinical outcomes.
Efavirenz is primarily metabolised by hepatic CYP2B6
[7]. In the ACTG A5097s study, a gene-dose eﬀect for efa-
virenz pharmacokinetics was observed among patients with
CYP2B6 polymorphisms with three-fold-higher efavirenz
exposure among CYP2B6 516T/T homozygotes as compared
to G/G homozygotes, and with intermediate values for G/T
heterozygotes [13]. A subsequent analysis revealed that the
composite CYP2B6 516 G→T and 983 T→Cg e n o t y p eb e s t
predicted efavirenz pharmacokinetics, suggesting a slow-
metaboliser genotype for efavirenz. Among Caucasians, this
genotype was associated with a ﬁrst CNS adverse event (P =
0.04). Surprisingly, among Black patients (in whom slow-
metaboliser genotypes are more frequent), no association
was found [14]. Instead, Black patients with the slow-me-
taboliser genotype had a lower incidence of virologic failure
than other races (P = 0.02) [14]. The authors of that
study postulated that higher efavirenz concentrations among
patients with the slow-metaboliser genotype could permit
continued suppression of HIV-1 during episodes of treat-
ment interruption [14].
Therefore, the clinical relevance of the moderately in-
creased efavirenz concentrations observed with food in the
current study is a balance between the risk of increased tox-
icity (at the onset of therapy) and the potential beneﬁt of
higher efavirenz exposures leading to a lower incidence of
virologic failure, based on the assumption that dosing efa-
virenz with food would have analogous eﬀects to those seen
among Blacks with the slow-metaboliser genotype in the
ACTG study.AIDS Research and Treatment 5
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Figure 2: Individual pharmacokinetic parameters for (a) tenofovir and (b) emtricitabine when administered in the fed and fasting states.
(c) Individual pharmacokinetic parameters for efavirenz when administered in the fed and fasting states.
In the present study, only two patients had efavirenz
concentrations in the expected range for patients with the
CYP2B6 516TT genotype. For other patients, food mod-
estly increased exposure, but absolute concentrations did
not attain values of the two patients under either meal
condition.Althoughthegenotypeofthosetwopatientsisnot
known, one can postulate that genetic inﬂuence on efavirenz
metabolism plays a more signiﬁcant role than food on
efavirenz pharmacokinetics and efavirenz-related toxicity.
Although the patients in the current study reported no
adverse events, formal psychometric testing was not con-
ducted and mild changes in CNS function cannot be com-
pletely ruled out. Importantly, these patients had received
efavirenz-basedtherapyforaminimumofsevenmonthspri-
or to enrolment. Since efavirenz-related CNS toxicity tends
to resolve within the ﬁrst few weeks of treatment [7], the
safety ﬁndings of the current study may not be representative
of safety outcomes among patients initiating efavirenz-based
regimens. Nevertheless, the ﬁndings from the current study
suggest that stable patients may administer efavirenz-con-
taining regimens without meal restrictions.
For tenofovir, peak concentrations were unaﬀected by
food intake while tenofovir exposure was marginally in-
creased by food. Emtricitabine exposure and peak concen-
trations were only mildly reduced (13% and 17%, resp.)
by a meal. Tenofovir is a nucleotide reverse transcriptase6 AIDS Research and Treatment
inhibitor which undergoes intracellular phosphorylation in
two steps to its active diphosphate anabolite. Like teno-
fovir,emtricitabineundergoesintracellularphosphorylation.
However, emtricitabine undergoes phosphorylation in three
stepstoitsactivetriphosphate.Forthesetwodrugs,mildand
transient changes in plasma concentrations are unlikely to be
of clinical relevance as drug eﬀect is not only dependent on
absorption and elimination but also on the rate and extent of
intracellular phosphorylation [15]. Consequently, TDF and
emtricitabine may be taken with or without food.
In general, for lipophilic drugs, absorption is improved
by food, particularly food containing fat [16]. Efavirenz is
lipophilic,andenhancedabsorptionwithfatisexpected.The
diester derivative of tenofovir (TDF) was speciﬁcally devel-
oped to improve the lipophilicity of tenofovir and enhance
oral bioavailability [17, 18]; thus, enhanced absorption with
fat would also be expected. The increases in tenofovir
exposure seen in the current study were of lesser magnitude
than those reported with single-dose TDF which may relate
to less fat being used in the present study than the single-
dosestudywhichhad50%ofthecaloriesofa700–1,000 Kcal
meal derived from fat [6]. In contrast to TDF and efavirenz,
emtricitabine is an acidic hydrophilic molecule [19]. Fat may
interfere with emtricitabine dissolution, and food may delay
dissolution of the tablet by reducing gastric pH, resulting in
lower emtricitabine exposures with food.
In conclusion, a fat-containing meal moderately in-
creased efavirenz steady-state peak concentrations. In con-
trast, pharmacokinetic parameters of tenofovir and em-
tricitabine were mildly aﬀected by food, and those changes
do not appear clinically signiﬁcant. Since efavirenz-related
central nervous system toxicity may be concentration depen-
dent, patients experiencing these toxicities should take the
FDC tablet without food. However, for patients without
toxicities, the FDC can be taken without regard to meals.
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